Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study identified a novel mechanism by which dsRNA-induced TLR3 activation and retinoic acid pathways contribute to new hair follicle formation after deep wounds in mice and suggested a similar potential in humans.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study identified a missense mutation in the rat Desmoglein 4 gene, causing abnormal hair shaft development in lanceolate hair mutant rats by disrupting a critical calcium binding site.

This review discusses the role of LPA(3) in embryo implantation and its genetic connection with prostaglandin signaling, but reports no new clinical results.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

Ritlecitinib works well and is safe for treating alopecia areata.

This study found that RANKL promotes the regeneration of type II alveolar epithelial cells in lung tissue, suggesting it may play a role in lung repair processes for diseases like COPD and fibrosis.

This study explored how long non-coding RNA mediates the effects of FGF5 on the hair follicle development and villus growth of Liaoning cashmere goats.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study reports that the Luce LDS 100 infrared light therapy shows positive hair growth results after one year in men and women with androgenetic alopecia.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

The LTF gene may help predict and manage nonspecific orbital inflammation.

This study found that the small signaling peptide RALF22 plays a key role in root hair growth response to volatile compounds emitted by Penicillium aurantiogriseum through ethylene, auxin, and photosynthesis signaling in Arabidopsis.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.